Drugs / AUT00201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05873062 | May 2023 → May 2024 | progressive myoclonus epilepsy | Autifony Therapeutics Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04158453 Comparator | Oct 2019 → Dec 2020 | — | Autifony Therapeutics Limited | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-13 | Autifony Therapeutics Limited | Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7) autifony.com ↗ |
| 2020-05-04 | Autifony Therapeutics Limited | Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders autifony.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUT00201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05873062 ↗ |
| Route | Oral | “Oral dose of AUT00201” NCT04158453 ↗ |